FDA product approval
not established. No US therapeutic product approval is established by this curated source set; other countries and products may differ.
Healing · compound · checked 2026-10-09
BPC-157 is a lab-made peptide (15 amino acids). Most papers are animal studies. One 2021 clinic series looked at knee pain. FDA reviewed compounding safety in 2026. There is no FDA-approved BPC-157 drug. WADA lists it under S0 at all times. This page reports cited status and listed vial sizes. It does not tell you to use it or how much to take. Read the vial.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
Sellers list BPC-157 as vials, sprays, and capsules. A listing is a listing. It does not prove every form matches the material in a paper. Lab work has looked at tissue repair, growth-factor, and nitric-oxide pathways. Those ideas stay ideas until a controlled human study of the same preparation answers a clinical question.
Laboratory studies explore tissue repair, growth-factor and nitric-oxide pathways. These mechanisms remain incompletely resolved in humans.
FDA product approval
not established. No US therapeutic product approval is established by this curated source set; other countries and products may differ.
Compounding
not established. FDA’s July 2026 advisory briefing recommended against 503A inclusion. An advisory recommendation is not a final rule, product approval or determination of every pharmacy’s eligibility.
Research
investigational. Early human observational reports and extensive preclinical hypotheses; controlled clinical benefit remains unresolved.
Sport
prohibited. WADA S0 names BPC-157 as prohibited at all times.
A 2021 knee-pain series looked back at 12 people who received BPC-157 alone. Eleven said they felt better. One did not. There was no control group. Follow-up was by phone. Some other clinic patients also received TB4, so the series cannot prove BPC-157 caused the change. FDA’s 2026 briefing collected a small set of human reports plus local reactions, breathing trouble, and skin-color changes. FDA said blame is weak because people often used other products and details are missing. A March 2026 public thread has better, no-change, and mood-change comments. Vote counts are not rates. A missing large trial does not prove “no effect.” Forum posts do not prove an effect. If the only human numbers you can find are twelve knees and a phone follow-up, that is the whole cited clinic record on this card.
We mark the cited papers as C. That is our label for how strong those papers are. It does not say the compound works.
human-observation
In a 2021 clinic series, 11 of 12 people receiving BPC-157 alone reported pain improvement and one did not.
12 BPC-only respondents within a 17-patient retrospective clinic series; some other patients also received TB4. Reported human outcomes exist. Retrospective selection, subjective telephone follow-up, absence of a control group and limited safety monitoring prevent causal efficacy or safety conclusions.
human-observation
FDA catalogued limited human studies and adverse reports with incomplete monitoring and substantial uncertainty.
Small published studies and spontaneous adverse-event reports, not a representative treated population. Events are reports, not confirmed substance-specific causation. Short studies and under-reporting cannot establish long-term safety.
community-report
A March 2026 community thread contains reports of knee-pain improvement, no improvement, mood flattening and no mood change.
Self-selected public commenters; identities, diagnoses, products and exposures are unverified. Vote counts are not outcome rates. Multiple substances, rehabilitation, natural recovery and reporting bias confound interpretation. This is sourced experience, not a clinical study.
The catalog does not record a single hour value. No verified formulation-specific human estimate in this source set; no guessed value is supplied.
The vendor file lists 6 mg, 10 mg, and 20 mg labels. Follow the label on the vial you actually hold for temperature and light. This page does not set a throw-away date after you add water. Write the lot.
U-100 math for listed BPC-157 sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 6 mg | 60 | 30 | 20 |
| 10 mg | 100 | 50 | 33.3 |
| 20 mg | 200 | 100 | 66.7 |
People using PepBear often log: Dated pain, daily function, rehabilitation and activity records alongside existing clinician-directed observations. Record mood changes and symptoms as observations, including nonresponse; improvement does not establish structural tissue healing.
This source set shows no US drug approval as of Oct 9, 2026. FDA has published compounding-safety materials that mention BPC-157. That is not product approval.
If you type 10 mg and 2 mL, a U-100 syringe has 100 marks per mL, so each unit is 50 mcg of the dissolved mass. The calculator does that math on the numbers you type. It does not pick an amount for you.
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.